Source: http://www.google.com/patents/US7052699?dq=7,013,345/
Timestamp: 2018-01-20 15:47:27
Document Index: 262939530

Matched Legal Cases: ['Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 60', 'Application No. 60', 'Application No. 60']

Patent US7052699 - Immunogenic composition - Google Patents
The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine....http://www.google.com/patents/US7052699?utm_source=gb-gplus-sharePatent US7052699 - Immunogenic composition
Publication number US7052699 B2
Application number US 10/753,339
Also published as CA2398816A1, CN1635876A, EP1307130A1, EP1307130A4, US6982086, US7078039, US20010036461, US20040197344, US20050112136, US20060008467, WO2001056355A2
Publication number 10753339, 753339, US 7052699 B2, US 7052699B2, US-B2-7052699, US7052699 B2, US7052699B2
Patent Citations (61), Non-Patent Citations (82), Classifications (21), Legal Events (4)
US 7052699 B2
Alleies Americans Caucasians Indians Thais
A2 16.7 28.3 25.5 25.5
A3 8.9 12.2 2.9 1.5
B7 8.3 10.0 3.9 2.7
B8 3.2 10.0 5.6 0.2
*Frequencies for HLA-A and HLA-B alleies are taken from HLA 1991 [21], HLA-C for African Americans and USA Caucasians are taken from Histo-compatibility Testing 1984 [19], HLA-C for North American Indians from Williams and McAuley, 1992 [22], and HLA-C for Thais from the Proceedings of the Second Asia and Oceania Histocompatibility Workshop Conference [23].
A28, B14 gp41 583-592 VERYLKDQQL
b) USA Caucasians A2, A3, A11, B35 nef 73-82 QVPLRPMTYK
nef 120-144* YFPDWQNYTPGPGIRYPLTFGWCYK
e) African Americans A2, A3, A11, B35 nef 73-82 QVPLRPMTYK
USA Caucasians A28, B14 gp41 583-592 VERYLKDQQL
Indians A30, B8 gp41 844-863 RRIRQGLERALL
Thais B17, B37 nef 117-128 TQGYFPQWQNYT
Vaccine elements for
Peptide gp120 C4 Region gp120 V3 Region
C4-V3RF KQIINMWQEVGKAMYATRPNNNTRKSITKGPGRVIYATG
The peptides presented above correspond to the following sequence identifiers, respectively: SEQ ID NOs:95-101.
overlapping epitopes Th - CTL
11 A*-Th/M-CTL KQIINWQVVGKAMAYA- Bw62,Cw3,Cw8,Cw0401A2,A3,
US20010036461 Feb 5, 2001 Nov 1, 2001 Haynes Barton F. Human immunodeficiency virus vaccine
1 Abaza et al, "Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization", Journal of Protein Chemistry 11(5):433-444 (1992).
2 Ahlers, et al., "Candidate HIV Type 1 Multideteminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All using the Same Adjuvant Immunization", AIDS Research and Human Retroviruses, vol. 12, No. 4, pp. 259-272 (1996).
6 Bartlett et al, "Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen", AIDS 12:1291-1300 (1998).
8 Berzofsky, et al., "Antigenic Peptides Recognized by T lymphoctyes from AIDS Viral Envelope-Immune Humans", Nature, vol. 334, pp. 706-708 (1988).
11 Borrow et al, "Virus-Specific CD8+ Cytotoxic T-Lymphoctye Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection", Journal of Virology 68(9):6103-6110 (1994).
12 Cao et al, "Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection", N. Engl. J. Med. 332(4):201-208 (1995).
15 Cocchi et al, "Identification of RANTES, MIP-1alpha, and MIP-1beta as the Major HIV-Suppressive Factors Produced by CD8+ T Cells", Science 270:1811-1815 (1995).
16 Cruse et al, Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., p. 309, QR180.4.C78 (1995).
17 Database EPO Proteins 'Online!, Apr. 26, 1994, "antigen which binds to antibodies with an affinity for HIV-1 p24", retrieved from EBI accession No. EPOP:A18855 Database accession No. A18855 & WO 91/13360 A (Replico Medical AB) Sep. 5, 1991 -XP002303507.
18 Database EPO Proteins 'Online!, Apr. 26, 1994, "antigen which binds to antibodies with an affinity for HIV-1 p24", retrieved from EBI accession No. EPOP:A18953 Database accession No. A18953 & WO 91/13360 A (Replico Medical AB) Sep. 5, 1991 -XP002303508.
19 Database EPO Proteins 'Online!, Aug. 23, 1995, "Cytotoxic T lymphocyte epitope 19 derived from gap p17 (MA) protein.", retrieved from EBI accession No. GSN:AAR68762 Database accession No. AAR68762 & WO 94/28871 A (Endocon Inc) Dec. 22, 1994 -XP002303510.
20 Database EPO Proteins 'Online!, jUL. 14, 1993, "Cytotoxic T lymphocyte epitope 19 derived from gag p17 (MA) protein.", retrieved from EBI accession No. GSN:AAR68762 Database accession No. A04294 & WO 86/02383 A (Centre Nat. Rech. Scient. Pasteur Institut (FR)) Apr. 24, 1986 -XP002303509.
21 Database Gemeseq 'Online!, May 12, 1999, "T cell epitope/MHC ligand SEQ ID NO:226.", retrieved from EBI accession No. GSN:AAY10296, Database accession No. AAY10296 & WO 99/02183 A (Simard John J L; CTL Immunotherapies Corp (CA); Kuendig Thomas M (CH)) Jan. 21, 1999 -XP002303500.
22 Database Geneseq 'Online!, Feb. 22, 2000, HLA-A2-binding HIV-1 GP41 CTL epitope #250, retrieved from EBI accession No. GSN:AAY66448 Database accession No. AAY66448 & WO 99/49893 A (Univ Boston) Oct. 7, 1999 -XP002303504.
23 Database Geneseq 'Online!, Nov. 12, 1990, "Peptide component of AIDS vaccine.", retrieved from EBI accession No. GSN:AAP82469 Database accession No. AAP82469 & EP 0 273 716 A (US Health) Jul. 6, 1988 -XP002303505.
24 Database Geneseq 'Online!, Sep. 14, 1999 "HIV-derived lipopeptide epitope GAG253 for mixed micelles.", retrieved from EBI accession No. GSN:AAY26615 Database accession No. AAY26615 & WO 99/27954 A (Gras Masse Helene; Guillet Jean Gerard (FR); Inst. Nat. Sante Rech. Med) Jun. 10, 1999 -XP002303503.
25 Database USPTO Proteins 'Online!, Oct. 7, 1996, "Sequence 17 from patent US 5519114.", retrieved from EBI accession No. USPOP:AAB13195 Database accession No. AAB13195 & US 5 519 114 A (Johnson Howard M et al) May 21 1996 -XP002303506.
26 Feng et al, "HIV-1 Entry Cofactor Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor", Science 272:872-877 (1996).
28 Gao et al, "Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization", Journal of Virology, The American Society for Microbiology 70(3):1651-1667 (1996).
29 Goulder et al, "Novel, Cross-Restricted, Conserved, and Immunodominant Cytotoxic T Lymphocyte Epitopes in Slow Progressors in HIV Type I Infection", AIDS Research and Human Retroviruses 12(18):1691-1698 (1996).
32 Hardy, G.H., "Mendelian Proportions in a Mixed Population", Science, N.S. XXVIII, (706):49-50 (1908).
33 Hart, et al., "Priming of an Anti-Human Immunodeficiency Virus (HIV) CD8+ Cytotoxic T Cells In Vivo by Carrier-Free HIV Synthetic Peptides", Proc. Natl. Acad. Sci. USA, vol. 88, pp. 9448-9452 (1991).
34 Haynes et al, "HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen", AIDS Research and Human Retroviruses 11(2):211-221 (1995).
35 Haynes et al, "HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3-Peptides as a Polyvalent Immunogen", AIDS Research and Human Retroviruses 11(2):211-221 (1995).
36 Haynes et al, "Toward an Understanding of the Correlates of Protective Immunity to HIV Infection", Science 271:324-328 (1996).
37 Haynes et al, "Use of Synthetic Peptides in Primates to Induce High-Titered Neutralizing Antibodies and MCH Class I-Restricted Cytotoxic T Cells Against Acquired Immunodeficiency Syndrome Retroviruses: An HLA-Based Vaccine Strategy", Transactions of the Association of American Physicians 106:33-41 (1993).
49 Mayr et al, "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parental Vaccination and Behavior in Organisms with a Debilitated Defence Mechanism", Zbl. Bakt. Hyg. I. Abt. Orig. B 167:375-390 (1978) Only the English abstract considered.
50 Mellors et al, "Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion", Ann. Intern. Med. 122:573-579 (1995).
51 Michel et al, "HIV-1 Env, Nef, and Gag-specific T-Cell Immunity in Mice: Conserved Epitopes in NefP27 and Gag P25 Proteins", AIDS Research and Human Retroviruse 8(4):469-478 (1992).
52 Mills et al, "HIV p24-specific Helper T Cell Clones from Immunized Primates Recognize Highly Conserved Regions of HIV-1", J. Immunol. 144:1677-1683 (1990).
54 Novitsky et al, "Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef- Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design", Journal of Virology 75(19):9210-9228 (2001).
55 Nowak et al, "Antigenic oscillations and shifting Immunodominance in HIV-1 Infections", Nature 375:606-611 (1995).
56 Oscherwitz et al, "A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogeicity by facilitating helper T-cell responses to a covalently linked carrier protein", Vaccine 17:2392-2399 (1999).
57 Palker et al, "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen Comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes", The Journal of Immunology 142:3612-3619 (1989).
58 Pantaleo et al, "Major expansion of CD8+ T cells with a predominant Vbeta usage during the primary Immune response to HIV", Nature 3970:463-467 (1994).
59 Pantaleo et al, "Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection", N. Engl. J. Med. 332(4):209-216 (1995).
60 Paul, Fundamental Immunology (Philadelphia & New York, Lippincott-Raven Publishers, pp. 250, 1311, 1312, QR.181.F84 (1993).
62 Riffkin et al, "A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus", Gene 167:279-283 (1995).
65 Rowland-Jones et al, HIV-Specific Cytotoxic T-Cells in HIV-Exposed but Uninfected Gambian Women, Nat. Med. 1(1):59-64 (1995) (Abstract) complete ref. next page.
69 Sullivan et al, "Replicative Function and Neutralization Sensitivity of Envelope Glycoproteins from Primary and T-Cell Line-Passaged Human Immunodeficiency Virus Type 1 Isolates", Journal of Virology 69(7):4413-4422 (1995).
70 U.S. Patent Application No. 10/518,523 filed Dec. 21, 2004 (U.S. National Phase of WO 2004/009785 see above).
71 U.S. Patent Application No. 10/973,475 filed Oct. 27, 2004.
72 U.S. Patent Application No. 10/973,977 filed Oct. 27, 2004.
73 U.S. Provisional Application No. 60/503,460 filed Sep. 17, 2003 and U.S. Provisional Application No. 60/604,722 filed Aug. 27, 2004 (see attached copy of WO 2005/028625).
74 U.S. Provisional Application No. 60/625,720 filed Nov. 8, 2004.
78 Ward et al, "Analysis of HLA-Frequencies in Population Cohorts for Design of HLA-Based HIV Vaccines", HIV Molecular Database, pp. IV-10-IV-16 (1995).
79 Wei et al, "Viral dynamics in human immunodeficiency virus type 1 infection", 373:117-122 (1995).
81 Wilson et al, "Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficieny Virus Type 1-Derived Helper T-Lymphocyte Epitopes", Journal of Virology 75(9):4195-4207 (2001).
U.S. Classification 424/192.1, 424/185.1, 424/188.1, 530/324, 424/186.1, 530/350, 530/826, 424/208.1
International Classification C07K14/725, C12N15/09, A61K39/21, A61P31/18, C07K14/16, A61K39/00
Cooperative Classification Y10S530/826, C12N2740/15022, C12N2740/16034, C07K14/005, A61K2039/57, C12N2740/16122